Spatial and Temporal Pattern of Ischemia and Abnormal Vascular Function Following Traumatic Brain Injury.
Journal
JAMA neurology
ISSN: 2168-6157
Titre abrégé: JAMA Neurol
Pays: United States
ID NLM: 101589536
Informations de publication
Date de publication:
01 03 2020
01 03 2020
Historique:
pubmed:
12
11
2019
medline:
13
2
2021
entrez:
12
11
2019
Statut:
ppublish
Résumé
Ischemia is an important pathophysiological mechanism after traumatic brain injury (TBI), but its incidence and spatiotemporal patterns are poorly characterized. To comprehensively characterize the spatiotemporal changes in cerebral physiology after TBI. This single-center cohort study uses 15oxygen positron emission tomography data obtained in a neurosciences critical care unit from February 1998 through July 2014 and analyzed from April 2018 through August 2019. Patients with TBI requiring intracranial pressure monitoring and control participants were recruited. Cerebral blood flow (CBF), cerebral blood volume (CBV), cerebral oxygen metabolism (CMRO2), and oxygen extraction fraction. Ratios (CBF/CMRO2 and CBF/CBV) were calculated. Ischemic brain volume was compared with jugular venous saturation and brain tissue oximetry. A total of 68 patients with TBI and 27 control participants were recruited. Results from 1 patient with TBI and 7 health volunteers were excluded. Sixty-eight patients with TBI (13 female [19%]; median [interquartile range (IQR)] age, 29 [22-47] years) underwent 90 studies at early (day 1 [n = 17]), intermediate (days 2-5 [n = 54]), and late points (days 6-10 [n = 19]) and were compared with 20 control participants (5 female [25%]; median [IQR] age, 43 [31-47] years). The global CBF and CMRO2 findings for patients with TBI were less than the ranges for control participants at all stages (median [IQR]: CBF, 26 [22-30] mL/100 mL/min vs 38 [29-49] mL/100 mL/min; P < .001; CMRO2, 62 [55-71] μmol/100 mL/min vs 131 [101-167] μmol/100 mL/min; P < .001). Early CBF reductions showed a trend of high oxygen extraction fraction (suggesting classical ischemia), but this was inconsistent at later phases. Ischemic brain volume was elevated even in the absence of intracranial hypertension and highest at less than 24 hours after TBI (median [IQR], 36 [10-82] mL), but many patients showed later increases (median [IQR] 6-10 days after TBI, 24 [4-42] mL; across all points: patients, 10 [5-39] mL vs control participants, 1 [0-3] mL; P < 001). Ischemic brain volume was a poor indicator of jugular venous saturation and brain tissue oximetry. Patients' CBF/CMRO2 ratio was higher than controls (median [IQR], 0.42 [0.35-0.49] vs 0.3 [0.28-0.33]; P < .001) and their CBF/CBV ratio lower (median [IQR], 7.1 [6.4-7.9] vs 12.3 [11.0-14.0]; P < .001), suggesting abnormal flow-metabolism coupling and vascular reactivity. Patients' CBV was higher than controls (median [IQR], 3.7 [3.4-4.1] mL/100 mL vs 3.0 [2.7-3.6] mL/100 mL; P < .001); although values were lower in patients with intracranial hypertension, these were still greater than controls (median [IQR], 3.7 [3.2-4.0] vs 3.0 [2.7-3.6] mL/100 mL; P = .002), despite more profound reductions in partial pressure of carbon dioxide (median [IQR], 4.3 [4.1-4.6] kPa vs 4.7 [4.3-4.9] kPa; P = .001). Ischemia is common early, detectable up to 10 days after TBI, possible without intracranial hypertension, and inconsistently detected by jugular or brain tissue oximetry. There is substantial between-patient and within-patient pathophysiological heterogeneity; ischemia and hyperemia commonly coexist, possibly reflecting abnormalities in flow-metabolism coupling. Increased CBV may contribute to intracranial hypertension but can coexist with abnormal CBF/CBV ratios. These results emphasize the need to consider cerebrovascular pathophysiological complexity when managing patients with TBI.
Identifiants
pubmed: 31710336
pii: 2753780
doi: 10.1001/jamaneurol.2019.3854
pmc: PMC6865302
doi:
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
339-349Subventions
Organisme : Medical Research Council
ID : G0900903
Pays : United Kingdom
Organisme : Medical Research Council
ID : G9439390
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0600986
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0001237
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 093267
Pays : United Kingdom
Références
J Cereb Blood Flow Metab. 2004 Feb;24(2):191-201
pubmed: 14747746
J Neurosurg. 2000 Aug;93(2):183-93
pubmed: 10930002
J Neurosurg. 1997 Jul;87(1):9-19
pubmed: 9202259
J Cereb Blood Flow Metab. 2009 May;29(5):965-75
pubmed: 19293825
Lancet. 1975 Mar 1;1(7905):480-4
pubmed: 46957
J Neurol Neurosurg Psychiatry. 1989 Mar;52(3):346-50
pubmed: 2926419
J Neurosurg. 2000 Nov;93(5):815-20
pubmed: 11059663
Front Neurol. 2014 Jul 07;5:114
pubmed: 25071702
J Cereb Blood Flow Metab. 2004 Feb;24(2):202-11
pubmed: 14747747
JAMA Neurol. 2016 May 1;73(5):542-50
pubmed: 27019039
J Cereb Blood Flow Metab. 1987 Jun;7(3):372-4
pubmed: 3584270
Br Med Bull. 1999;55(1):226-58
pubmed: 10695089
Lancet. 1971 Feb 6;1(7693):265-6
pubmed: 4100017
J Neurotrauma. 2013 Mar 1;30(5):352-60
pubmed: 23461651
Neurocrit Care. 2008;9(3):319-25
pubmed: 18563636
J Comput Assist Tomogr. 1980 Dec;4(6):727-36
pubmed: 6971299
J Nucl Med. 1996 Jul;37(7):1166-70
pubmed: 8965189
Crit Care Med. 2005 Jan;33(1):189-95; discussion 255-7
pubmed: 15644668
J Cereb Blood Flow Metab. 2010 Apr;30(4):883-94
pubmed: 20029449
Crit Care Med. 2007 Feb;35(2):568-78
pubmed: 17205016
Crit Care Med. 2004 Jun;32(6):1384-90
pubmed: 15187523
J Cereb Blood Flow Metab. 1989 Dec;9(6):723-42
pubmed: 2684991
J Cereb Blood Flow Metab. 2005 Jun;25(6):763-74
pubmed: 15716852
Brain. 2005 Aug;128(Pt 8):1931-42
pubmed: 15888537
Lancet Neurol. 2017 Jun;16(6):452-464
pubmed: 28504109
J Neurol Sci. 1978 Dec;39(2-3):213-34
pubmed: 739268
Crit Care Med. 2008 Jan;36(1):273-81
pubmed: 18090356
Neurology. 2006 Oct 10;67(7):1165-71
pubmed: 17030747
J Neurosurg. 2002 Jan;96(1):103-8
pubmed: 11794590
Neurosci Bull. 2014 Oct;30(5):857-62
pubmed: 25085575
Brain Res. 2015 Dec 2;1628(Pt B):288-297
pubmed: 26341532
J Neurosurg. 2000 Jan;92(1):7-13
pubmed: 10616076
Curr Opin Crit Care. 2006 Apr;12(2):85-9
pubmed: 16543781
Cell Mol Neurobiol. 2017 May;37(4):571-585
pubmed: 27383839
Brain. 1998 Jul;121 ( Pt 7):1369-79
pubmed: 9679787
Neurosurgery. 2019 Jul 1;85(1):E75-E82
pubmed: 30476233
Brain. 2004 Nov;127(Pt 11):2479-90
pubmed: 15456706
Intensive Care Med. 2004 Dec;30(12):2180-7
pubmed: 15480563
Acta Neurochir Suppl. 2003;86:7-10
pubmed: 14753394
J Neurosurg. 2007 Apr;106(4):526-9
pubmed: 17432700
Neurosurgery. 2017 Jan 01;80(1):6-15
pubmed: 27654000
Crit Care Med. 1999 Nov;27(11):2337-45
pubmed: 10579245
Acta Neurochir Suppl. 2008;102:241-5
pubmed: 19388323